Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 14, 2026

Should You Buy, Sell or Hold Amazon (AMZN) Stock at $245?

View original at finance.yahoo.com
“the company generated operating income of $79.98 billion across its segments”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Amazon flagged tariff and trade policy uncertainty, foreign exchange volatility, and recessionary fears as active risks in guidance

    60% confidence
  • Bulls see three highest-margin segments (AWS, advertising, and third-party services) all accelerating simultaneously

    60% confidence
  • Bears argue the stock at $240 prices in a best-case AI buildout while underweighting risks that consumer spending softens or enterprise cloud budgets tighten

    60% confidence
  • Customers wanting to run their AI workloads where the rest of their applications and data are creates a compounding effect, pulling core cloud migration spend alongside AI investment

    60% confidence
  • Amazon holds a Hold rating at $245 as CapEx surge pressures near-term returns

    60% confidence

Data points we hold from this source

Amazon Web Services · annualized revenue run rate142 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com